As per the agreement, Mayo Clinic and Oxford BioMedica will take up clinical studies on glaucoma treatment using Oxford BioMedica’s LentiVector gene delivery technology.
The technology expresses a COX-2 gene and a PGF-2a receptor gene in order to reduce intraocular pressure.
Under the terms of the collaboration, Oxford BioMedica can exercise the exclusive US rights to license Mayo Clinic’s glaucoma technology, following the completion of pre-clinical studies.